List view / Grid view
A statement from scientists has highlighted that improving the understanding of COVID-19 infections in children will help researchers to develop better treatments.
The developers of an RNA imaging technology are using it to create a COVID-19 coronavirus testing kit, able to recognise the viral genome.
A new Cas13 RNA screen has been used to establish guide RNAs for the COVID-19 coronavirus and human RNA segments which could be used in vaccines, therapeutics and diagnostics.
AbCellera and Eli Lilly have announced their partnership to develop, manufacture and distribute antibody treatments for the COVID-19 coronavirus.
Researchers reveal that a broad range of immune cells react to COVID-19 and aid recovery, findings which could inform the development of a potential vaccine.
A new 3D model of the surface of the coronavirus COVID-19 has been released, to aid researchers in the development of a treatment.
The team used data from SARS-CoV to identify possible viral epitopes that vaccines could include to stimulate an immune response.
13 March 2020 | By
Welcome to Drug Target Review’s hub for COVID-19 research. Although much progress has been made since the start of the pandemic to combat COVID-19, the search for effective therapeutics and vaccines continues. Below you will find all the latest news and updates relating to SARS-CoV-2 studies, including disease research, drug…
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
Researchers have used cryogenic electron microscopy to show that coronaviruses enter human cells through an interaction with angiotensin-converting enzyme 2 (ACE2).
Researchers have demonstrated how the drug known as remdesivir works, presenting the viral RNA polymerase of coronaviruses as a target for these conditions.
Drug Target Review’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines.
A promising route for tackling the often-fatal MERS-coronavirus (MERS-CoV) has been identified by researchers in Germany.
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
